Daniel Herchenhorn, Carlos G Ferreira. Show Affiliations »
Abstract
Entities: Disease Gene
Mesh： See more » AnimalsAntineoplastic Agents/administration & dosageAntineoplastic Combined Chemotherapy Protocols/adverse effectsAntineoplastic Combined Chemotherapy Protocols/therapeutic useCarcinoma, Squamous Cell/drug therapyCarcinoma, Squamous Cell/enzymologyCarcinoma, Squamous Cell/pathologyCarcinoma, Squamous Cell/radiotherapyChemotherapy, AdjuvantErbB Receptors/antagonists & inhibitorsErbB Receptors/metabolismGefitinibHead and Neck Neoplasms/drug therapyHead and Neck Neoplasms/enzymologyHead and Neck Neoplasms/pathologyHead and Neck Neoplasms/radiotherapyHumansMolecular Targeted TherapyPatient SelectionProtein Kinase Inhibitors/administration & dosageQuinazolines/administration & dosageRadiation ToleranceRadiotherapy, AdjuvantTreatment Outcome
Substances： See more » Antineoplastic AgentsProtein Kinase InhibitorsQuinazolinesEGFR protein, humanErbB ReceptorsGefitinib
Year: 2011 PMID： 21300921 DOI： 10.1200/JCO.2010.33.8087
Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544